Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002254 · ClinicalTrials.gov registry record · NA
A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)
A NA study of HIV Infections, sponsored by Lederle Laboratories.
- Completed
- Registry status
- NA
- Development phase
- 3
- Study locations
NCT00002254: Completed NA study of HIV Infections, sponsored by Lederle Laboratories.
NCT00002254 is a NA study of HIV Infections that has completed, run by Lederle Laboratories. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002254, a NA study of HIV Infections, has completed, sponsored by Lederle Laboratories.
- COMPLETED
- Registry status
- NA
- Development phase
- 3
- Study locations
Study Summary
To assess the tolerance and toxicity profile of deoxy-3'-fluorothymidine (FLT) after multiple oral dosing for 16 weeks. To characterize the steady-state pharmacokinetics of FLT after multiple oral doses. To assess the effect of FLT on immunologic and virologic markers of HIV infection (CD4+ lymphocyte count, p24 antigen, viremia) in patients with AIDS or AIDS related complex (ARC) after multiple oral dosing for 16 weeks.
Conditions Studied
Interventions
- DRUG Alovudine
Study Locations (3)
Maryland
- Johns Hopkins Hosp - Baltimore
New York
- Mem Sloan - Kettering Cancer Ctr - New York
North Carolina
- Univ of North Carolina School of Medicine - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002254
The ClinicalTrials.gov registry entry for NCT00002254 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Lederle Laboratories, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Alovudine is the first listed.
NCT00002254 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00002254 about?
NCT00002254 is a clinical study titled "A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)". To assess the tolerance and toxicity profile of deoxy-3'-fluorothymidine (FLT) after multiple oral dosing for 16 weeks. To characterize the steady-state pharmacokinetics of FLT after multiple oral doses. To assess the effect of FLT on immunologic and virologic markers of HIV infection (CD4+ lymphocy...
What is the current status of trial NCT00002254?
This trial is currently completed. It is a NA study.
What conditions does trial NCT00002254 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002254?
The interventions under investigation include: Alovudine (DRUG).
Who is sponsoring clinical trial NCT00002254?
This trial is sponsored by Lederle Laboratories, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002254 being conducted?
This trial has 3 study locations across Maryland, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.